NAS10029,813+0.55%S&P7,744+0.28%GOLD$4,037−0.37%BTC$79,765−1.85%VIX17.26+2.07%latest tape · as of 08:02 UTC
The Screen · Healthcare · Medical Instruments & Supplies
Bausch + Lomb Corporation
BLCO · the NYSE · USD · Market cap $6.0B · 13,000 employees
Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, and internationally.
FAIL · Does not pass the screen
20.40 USD
Price as of 28 Oct 2026Daily close, not a live quote
Screened 2026-10-28 · the tape above runs as of 08:02 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
Key facts today
Price20.40 USD at the 28 Oct 2026 close
Ethical screenDoes not pass
OptionsOpen interest leans heavily to calls (put/call 0.13)
Last reviewed28 Oct 2026 (1 days ago)
A summary of the dated readings below, not a live quote and not advice.
PRICE · FAIR-VALUE RANGE1M3M6MYTD1Y3Y5Y
What this means: price 20.40 against the desk's fair-value range, base estimate 17.63, over the last year.
Positioning no disclosures inside 60 days, left as found
Options put/call open interest 0.13, read 2026-10-24
Ethical does not pass the values gate
Price20.40 USD
Fair value17.63
Ethical score70.0/100
Our investment reviews on this name
2026-10-27Read Markup16.93+20.5% to today ✓Markdown gives way to Markup with volume flow in agreement
2026-10-20Read Markdown16.66+22.4% to today Accumulation gives way to Markdown first Markdown read since October
2026-10-13Read Accumulation17.30+17.9% to today ✓Markdown gives way to Accumulation
2026-10-02Read Markdown16.94+20.4% to today Accumulation gives way to Markdown after a 12% rise in 13 weeks
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Bausch + Lomb Corporation holds its Markup at $20.40. Consolidating, no directional conviction, held for 317 days.
As held on the ledger · 2026-10-28
Phase
Markup
Quantitative state
Consolidating, no directional conviction, held for 317 days
Price at the screen
$20.40
Valuation
N/A trailing · 15.20 forward price to earnings
Values screen
FAIL· score 70.0
Beta
0.56
The Workings
Five Screens, Shown in Full
Does not pass. Debt ratio
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
36.24%
Below 33%
Interest-bearing debt is 36.2% of its assets, above the one-third ceiling the screen allows.
Fail
Interest-bearing cash
0.00%
Below 33%
Cash held in interest-bearing accounts and securities is 0.0% of assets, under the one-third limit.
Pass
Receivables
11.44%
Below 49%
Money owed to the company is 11.4% of assets, under the 49% limit.
Pass
Revenue purity
0.24%
Below 5%
Only 0.2% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Falls Short, in Plain English
Bausch + Lomb's business is in a permissible area, but its interest-bearing debt is about 36% of the company, just over the ~33% line, so it does not pass on the financial screens.
Read as at 2026-10-28. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when BLCO's ethical verdict changes
Today BLCO does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
Fair value range in USD, drawn from the 2026-10-28 screen. The gold marker is the market price at the same screen. The price runs 13.6% above the base estimate.
Third-party analyst targets: 14 covering, consensus Buy. The average target sits −6% from the screen price.
Reading the gap · Both our model and the Street see limited upside at this price.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-10-28 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Eye care supplier clears ethical bar but little else
Think of Bausch + Lomb as the firm keeping contact lenses, eye drops and surgical kits flowing to clinics from Toronto to Tokyo. Revenue is rising nine percent, yet the business posts a four percent loss margin and negative three percent return on equity, leaving our calculated fair value only three percent above the current price. With an opportunity rating of none, this one stays on the shelf.
The forward multiple of fifteen times offers no cushion once the losses are factored in. Eleven analysts lean buy with a median target of eighteen dollars, but our screen sees no meaningful discount to intrinsic worth and an unknown competitive moat.
Profit recovery could take longer than expected in a sector where pricing pressure and regulatory delays are routine. Analysis, not advice.
The risks · The things to watch: its business and earnings are exposed to Canada and to currency swings.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
BLCO trades on the NYSE (the company is based in Canada). As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-10-27Markup · changed$16.93+1.6%Entry 9
The framework has shifted from markdown to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 1.6% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 4% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 22%. Our forward projection puts the odds of a 10% gain over the next month near 23%. The street (13 analysts) rates it hold, with a mean price target of $18.
2026-10-20Markdown · changed$16.66-3.7%Entry 8
The framework has shifted from accumulation to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 3.7% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 0% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 22%. Our forward projection puts the odds of a 10% gain over the next month near 23%. The street (13 analysts) rates it hold, with a mean price target of $18.
The framework has shifted from markdown to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 2.1% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 3% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 22%. Our forward projection puts the odds of a 10% gain over the next month near 23%. The street (13 analysts) rates it hold, with a mean price target of $18.
2026-10-02Markdown · changed$16.94+3.6%Entry 6
The framework has shifted from accumulation to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 3.6% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 3% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 22%. Our forward projection puts the odds of a 10% gain over the next month near 23%. The street (13 analysts) rates it hold, with a mean price target of $18.
2026-08-23Accumulation$16.35+0.6%Entry 5
Our analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 0.6% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 3% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 22%. Our forward projection puts the odds of a 10% gain over the next month near 23%. The street (13 analysts) rates it hold, with a mean price target of $18.
2026-07-23Accumulation$16.26+7.8%Entry 4
Our analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 7.8% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 3% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 22%. Our forward projection puts the odds of a 10% gain over the next month near 23%. The street (13 analysts) rates it hold, with a mean price target of $18.
2026-07-18Accumulation$15.08+0.0%Entry 3
Our analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 3% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 22%. Our forward projection puts the odds of a 10% gain over the next month near 23%. The street (13 analysts) rates it hold, with a mean price target of $18.
2026-07-03Accumulation$15.08+0.0%Entry 2
Our analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows modest positive risk-adjusted returns.
2026-07-02Accumulation$15.08Entry 1
Our analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows modest positive risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
